Shopping Cart 0
Cart Subtotal
USD 0

CASI Pharmaceuticals Inc (CASI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

CASI Pharmaceuticals Inc (CASI) is a biopharmaceutical company, which focuses on the acquisition, development and commercialization of innovative therapies for treating cancer and other unmet medical needs. Its pipeline product portfolio includes ENMD-2076 that is being developed globally for the treatment of various cancers including triple-negative breast cancer, soft-tissue sarcoma, ovarian clear cell carcinoma and fibrolamellar carcinoma. The company's pipeline also includes three in-licensed oncology products, namely, Zevalin for non-Hodgkin's lymphoma; Marqibo for acute lymphoblastic leukemia; and Evomela (melphalan) for multiple myeloma. The company operates subsidiaries in the US and China and a research and development center in Beijing, China. CASI is headquartered in Rockville, Maryland, the US.

CASI Pharmaceuticals Inc (CASI)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11

Asset Purchase 11

CASI Pharma Acquires HBV ANDA from Laurus Labs 11

CASI Pharma Acquires ANDA Portfolio from Sandoz 12

Licensing Agreements 13

Spectrum Pharma Enters into Licensing Agreement with CASI for Zevalin, Marqibo and Captisol-Enabled Melphalan 13

Equity Offering 15

CASI Pharma to Raise USD48.5 Million in Private Placement of Shares 15

CASI Pharma to Raise USD50 Million in Private Placement of Shares 16

CASI Pharma to Raise up to USD25 Million in Public Offering of Shares 17

CASI Pharma to Raise USD23.8 Million in Private Placement of Units 18

CASI Pharma Raises USD3 Million in Private Placement of Shares 19

CASI Pharma Raises USD7.8 Million in Final Tranche of Private Placement of Shares 20

CASI Pharma Raises USD1 Million in Third Tranche of Private Placement of Shares 21

CASI Pharma Raises USD6 Million in Second Tranche of Private Placement of Shares 22

CASI Pharma Raises USD10.3 Million in First Tranche of Private Placement of Shares and Warrants 23

Entremed Completes Private Placement Of Units For USD 11 Million 24

Debt Offering 25

EntreMed Completes Private Placement Of Convertible Notes Due 2012 For USD 10 Million 25

CASI Pharmaceuticals Inc-Key Competitors 27

CASI Pharmaceuticals Inc-Key Employees 28

CASI Pharmaceuticals Inc-Locations And Subsidiaries 29

Head Office 29

Other Locations & Subsidiaries 29

Recent Developments 30

Financial Announcements 30

Aug 14, 2018: CASI Pharmaceuticals announces second quarter and first half 2018 financial and business results 30

May 15, 2018: CASI Pharmaceuticals Announces First Quarter 2018 Financial And Business Results 32

Mar 29, 2018: CASI Pharmaceuticals Reports Fourth Quarter And Full Year 2017 Financial Results 34

Nov 14, 2017: CASI Pharmaceuticals Reports Third Quarter 2017 Financial Results 36

Aug 14, 2017: CASI Pharmaceuticals Reports Second Quarter 2017 Financial Results 37

May 15, 2017: CASI Pharmaceuticals Reports First Quarter 2017 Financial Results 38

Mar 31, 2017: CASI Pharmaceuticals Reports 2016 Fourth Quarter And Full Year Financial Results 39

Corporate Communications 40

Oct 02, 2018: CASI Pharmaceuticals appoints Larry Zhang as president to its China operations to lead commercialization 40

Jul 03, 2018: CASI Pharmaceuticals Added To Russell 2000, 3000 And Microcap Indexes 41

Product News 42

03/28/2017: CASI Pharmaceuticals Announces Poster Presentations At AACR Annual Meeting 42

Clinical Trials 43

Dec 01, 2017: CASI Pharmaceuticals Announces Poster Presentation At The 2017 San Antonio Breast Cancer Symposium (SABCS) On ENMD-2076 In Patients With Triple-Negative Breast Cancer (TNBC) 43

Sep 07, 2017: CASI Provides Update on its Cancer Drug Candidate, ENMD-2076 44

May 30, 2017: CASI Pharmaceuticals Announces Poster Presentation At ASCO On ENMD-2076 In Patients With Clear Cell Ovarian Carcinoma 45

May 18, 2017: CASI Pharmaceuticals Announces Abstract On ENMD-2076 In Clear Cell Ovarian Cancer 46

Apr 14, 2017: CASI Pharmaceuticals Reports On Enrollment Status Of ENMD-2076 Phase 2 Study In Triple-Negative Breast Cancer 47

Appendix 48

Methodology 48

About GlobalData 48

Contact Us 48

Disclaimer 48


List Of Figure

List of Figures

CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

CASI Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

CASI Pharma Acquires HBV ANDA from Laurus Labs 11

CASI Pharma Acquires ANDA Portfolio from Sandoz 12

Spectrum Pharma Enters into Licensing Agreement with CASI for Zevalin, Marqibo and Captisol-Enabled Melphalan 13

CASI Pharma to Raise USD48.5 Million in Private Placement of Shares 15

CASI Pharma to Raise USD50 Million in Private Placement of Shares 16

CASI Pharma to Raise up to USD25 Million in Public Offering of Shares 17

CASI Pharma to Raise USD23.8 Million in Private Placement of Units 18

CASI Pharma Raises USD3 Million in Private Placement of Shares 19

CASI Pharma Raises USD7.8 Million in Final Tranche of Private Placement of Shares 20

CASI Pharma Raises USD1 Million in Third Tranche of Private Placement of Shares 21

CASI Pharma Raises USD6 Million in Second Tranche of Private Placement of Shares 22

CASI Pharma Raises USD10.3 Million in First Tranche of Private Placement of Shares and Warrants 23

Entremed Completes Private Placement Of Units For USD 11 Million 24

EntreMed Completes Private Placement Of Convertible Notes Due 2012 For USD 10 Million 25

CASI Pharmaceuticals Inc, Key Competitors 27

CASI Pharmaceuticals Inc, Key Employees 28

CASI Pharmaceuticals Inc, Other Locations 29

CASI Pharmaceuticals Inc, Subsidiaries 29

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

CASI Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

CASI Pharmaceuticals Inc (CASI) is a biopharmaceutical company, which focuses on the acquisition, development and commercialization of innovative therapies for treating cancer and other unmet medical needs. Its pipeline product portfolio includes ENMD-2076 that is being developed globally for the treatment of various cancers including triple-negative breast cancer, soft-tissue sarcoma, ovarian clear cell carcinoma and fibrolamellar carcinoma. The company's pipeline also includes three in-licensed oncology products, namely, Zevalin for non-Hodgkin's lymphoma; Marqibo for acute lymphoblastic leukemia; and Evomela (melphalan) for multiple myeloma. The company operates subsidiaries in the US and China and a research and development center in Beijing, China. CASI is headquartered in Rockville, Maryland, the US.

CASI Pharmaceuticals Inc (CASI)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11

Asset Purchase 11

CASI Pharma Acquires HBV ANDA from Laurus Labs 11

CASI Pharma Acquires ANDA Portfolio from Sandoz 12

Licensing Agreements 13

Spectrum Pharma Enters into Licensing Agreement with CASI for Zevalin, Marqibo and Captisol-Enabled Melphalan 13

Equity Offering 15

CASI Pharma to Raise USD48.5 Million in Private Placement of Shares 15

CASI Pharma to Raise USD50 Million in Private Placement of Shares 16

CASI Pharma to Raise up to USD25 Million in Public Offering of Shares 17

CASI Pharma to Raise USD23.8 Million in Private Placement of Units 18

CASI Pharma Raises USD3 Million in Private Placement of Shares 19

CASI Pharma Raises USD7.8 Million in Final Tranche of Private Placement of Shares 20

CASI Pharma Raises USD1 Million in Third Tranche of Private Placement of Shares 21

CASI Pharma Raises USD6 Million in Second Tranche of Private Placement of Shares 22

CASI Pharma Raises USD10.3 Million in First Tranche of Private Placement of Shares and Warrants 23

Entremed Completes Private Placement Of Units For USD 11 Million 24

Debt Offering 25

EntreMed Completes Private Placement Of Convertible Notes Due 2012 For USD 10 Million 25

CASI Pharmaceuticals Inc-Key Competitors 27

CASI Pharmaceuticals Inc-Key Employees 28

CASI Pharmaceuticals Inc-Locations And Subsidiaries 29

Head Office 29

Other Locations & Subsidiaries 29

Recent Developments 30

Financial Announcements 30

Aug 14, 2018: CASI Pharmaceuticals announces second quarter and first half 2018 financial and business results 30

May 15, 2018: CASI Pharmaceuticals Announces First Quarter 2018 Financial And Business Results 32

Mar 29, 2018: CASI Pharmaceuticals Reports Fourth Quarter And Full Year 2017 Financial Results 34

Nov 14, 2017: CASI Pharmaceuticals Reports Third Quarter 2017 Financial Results 36

Aug 14, 2017: CASI Pharmaceuticals Reports Second Quarter 2017 Financial Results 37

May 15, 2017: CASI Pharmaceuticals Reports First Quarter 2017 Financial Results 38

Mar 31, 2017: CASI Pharmaceuticals Reports 2016 Fourth Quarter And Full Year Financial Results 39

Corporate Communications 40

Oct 02, 2018: CASI Pharmaceuticals appoints Larry Zhang as president to its China operations to lead commercialization 40

Jul 03, 2018: CASI Pharmaceuticals Added To Russell 2000, 3000 And Microcap Indexes 41

Product News 42

03/28/2017: CASI Pharmaceuticals Announces Poster Presentations At AACR Annual Meeting 42

Clinical Trials 43

Dec 01, 2017: CASI Pharmaceuticals Announces Poster Presentation At The 2017 San Antonio Breast Cancer Symposium (SABCS) On ENMD-2076 In Patients With Triple-Negative Breast Cancer (TNBC) 43

Sep 07, 2017: CASI Provides Update on its Cancer Drug Candidate, ENMD-2076 44

May 30, 2017: CASI Pharmaceuticals Announces Poster Presentation At ASCO On ENMD-2076 In Patients With Clear Cell Ovarian Carcinoma 45

May 18, 2017: CASI Pharmaceuticals Announces Abstract On ENMD-2076 In Clear Cell Ovarian Cancer 46

Apr 14, 2017: CASI Pharmaceuticals Reports On Enrollment Status Of ENMD-2076 Phase 2 Study In Triple-Negative Breast Cancer 47

Appendix 48

Methodology 48

About GlobalData 48

Contact Us 48

Disclaimer 48


List Of Figure

List of Figures

CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

CASI Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

CASI Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

CASI Pharma Acquires HBV ANDA from Laurus Labs 11

CASI Pharma Acquires ANDA Portfolio from Sandoz 12

Spectrum Pharma Enters into Licensing Agreement with CASI for Zevalin, Marqibo and Captisol-Enabled Melphalan 13

CASI Pharma to Raise USD48.5 Million in Private Placement of Shares 15

CASI Pharma to Raise USD50 Million in Private Placement of Shares 16

CASI Pharma to Raise up to USD25 Million in Public Offering of Shares 17

CASI Pharma to Raise USD23.8 Million in Private Placement of Units 18

CASI Pharma Raises USD3 Million in Private Placement of Shares 19

CASI Pharma Raises USD7.8 Million in Final Tranche of Private Placement of Shares 20

CASI Pharma Raises USD1 Million in Third Tranche of Private Placement of Shares 21

CASI Pharma Raises USD6 Million in Second Tranche of Private Placement of Shares 22

CASI Pharma Raises USD10.3 Million in First Tranche of Private Placement of Shares and Warrants 23

Entremed Completes Private Placement Of Units For USD 11 Million 24

EntreMed Completes Private Placement Of Convertible Notes Due 2012 For USD 10 Million 25

CASI Pharmaceuticals Inc, Key Competitors 27

CASI Pharmaceuticals Inc, Key Employees 28

CASI Pharmaceuticals Inc, Other Locations 29

CASI Pharmaceuticals Inc, Subsidiaries 29

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

CASI Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.